EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase I)

Phase I/Ib study evaluating safety, efficacy, pharmacokinetics and pharmacodynamics of NIZ985 monotherapy and in combination with an anti-PD-1 agent in patients with advanced solid tumors or lymphoma

Elena Garralda, Patrick Schöffski, Arjun Oberoi, Martin Schuler, Heike Richly, Paolo A Ascierto, Chia-Chi Lin, Rosa Álvarez, Sandip Pravin Patel, Yan Xing, Vivek Subbiah, Nancy Lewis und 10 weitere

European Journal of Cancer · 2026-08 · 244 · 116899

DOI: 10.1016/j.ejca.2026.116899 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2026-08. Verfasst von Elena Garralda und 21 weiteren Autor:innen. Beteiligte Einrichtung: Vall d'Hebron University Hospital (VHIO), Barcelona, Spain. Electronic address: egarralda@vhio.net. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Neoplasms, Lymphoma, Immune Checkpoint Inhibitors. Die Arbeit nennt 27 Literaturangaben. Gefördert von: Novartis Pharmaceuticals Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Heterodimeric IL-15 (NIZ985) shows rapid and indirect effects on different myeloid cells but may upregulate PD-1 (programmed cell death-protein 1) on CD8 + T cells, limiting its therapeutic potential. Combining IL-15 with an anti-PD-1 antibody is known to enhance antitumor immune response and prolong survival in mice. METHODS This was a phase I/Ib, open-label, multicenter study (NCT04261439) of NIZ985 single agent (SA) or with an anti-PD-1/CPI agent in patients with advanced solid tumors or lymphoma (responded and progressed on prior anti-PD-1) in a dose escalation (SA/with spartalizumab) and a dose expansion (with tislelizumab) arm. Primary objectives were to assess safety and tolerability including DLTs in cycle 1, adverse events (AEs) and serious AEs, dose interruptions, reductions, and dose intensity of NIZ985 SA and combination therapy. The recommended dose for expansion (RDE) for further investigations was determined. RESULTS NIZ985 was safe and well-tolerated, with a safety profile consistent with a previous investigation. Most common AEs with SA were injection site reaction, pyrexia, and transaminase increase. With combination therapy, AEs leading to dose adjustment/interruption were higher with NIZ985 16mg/kg compared to 8mg/kg and 12 mg/kg. NIZ985 exposure after the first dose increased with dose increases and was not affected by concomitant administration of CPIs. The RDE was determined to be 12 µg/kg NIZ985 QW (3 weeks on-1week off). CONCLUSIONS While NIZ985 is safe to use in combination with PD-1 inhibitors and showed biological activity, preliminary antitumor efficacy was limited in patients who previously progressed on an anti-PD-1/CPI agent.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsNeoplasmsLymphomaImmune Checkpoint InhibitorsInterleukin-15Programmed Cell Death 1 ReceptorHumansMaleFemaleMiddle AgedAgedAntibodies, Monoclonal, HumanizedAdultTreatment Outcome

Stichwörter der Autor:innen

Heterodimeric IL-15 Spartalizumab Tislelizumab Phase I/Ib clinical trial Solid…NIZ985

Substanzen

Antibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorsInterleukin-15spartalizumabProgrammed Cell Death 1 Receptortislelizumab

Autor:innen und Institutionen

  • Vall d'Hebron University Hospital (VHIO), Barcelona, Spain. Electronic address: egarralda@vhio.net.
  • University Hospitals Leuven, Department of General Medical Oncology, Leuven Cancer Institute KU Leuven, Leuven, Belgium.
  • Vall d'Hebron University Hospital (VHIO), Barcelona, Spain.
  • West German Cancer Center, University Hospital Essen, Essen, Germany.
  • Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Napoli, Italy; Università degli Studi di Napoli "Federico II", Napoli, Italy.
  • National Taiwan University Hospital, Taipei, Taiwan.

Förderung

  • Novartis Pharmaceuticals Corporation

Zitieren

APA

Garralda, E., Schöffski, P., Oberoi, A., Schuler, M., Richly, H., Ascierto, P. A., Lin, C. C., Álvarez, R., Patel, S. P., Xing, Y., Subbiah, V., Lewis, N., Patel, S., Wang-L-Akshman, L., Lee, J. B., Hassounah, N. B., Lee, L. H., Roy, M., Banerjee, S., …, & Shimizu, T. (2026). Phase I/Ib study evaluating safety, efficacy, pharmacokinetics and pharmacodynamics of NIZ985 monotherapy and in combination with an anti-PD-1 agent in patients with advanced solid tumors or lymphoma. European Journal of Cancer, 244, 116899. https://doi.org/10.1016/j.ejca.2026.116899

Vancouver

Garralda E, Schöffski P, Oberoi A, Schuler M, Richly H, Ascierto PA, et al. Phase I/Ib study evaluating safety, efficacy, pharmacokinetics and pharmacodynamics of NIZ985 monotherapy and in combination with an anti-PD-1 agent in patients with advanced solid tumors or lymphoma. European Journal of Cancer. 2026;244:116899. doi:10.1016/j.ejca.2026.116899

BibTeX
@article{Garralda2026,
  author = {Garralda, Elena and Schöffski, Patrick and Oberoi, Arjun and Schuler, Martin and Richly, Heike and Ascierto, Paolo A and Lin, Chia-Chi and Álvarez, Rosa and Patel, Sandip Pravin and Xing, Yan and Subbiah, Vivek and Lewis, Nancy and Patel, Shonika and Wang-L-Akshman, Lydia and Lee, Jong Bong and Hassounah, Nadia B and Lee, Lang Ho and Roy, Mike and Banerjee, Souvik and Reynolds, Aimee and Koyama, Takafumi and Shimizu, Toshio},
  title = {Phase I/Ib study evaluating safety, efficacy, pharmacokinetics and pharmacodynamics of NIZ985 monotherapy and in combination with an anti-PD-1 agent in patients with advanced solid tumors or lymphoma},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {244},
  pages = {116899},
  doi = {10.1016/j.ejca.2026.116899}
}
Kostenlos starten →